8-K: Enhabit Q3 2025: Strong Growth, Debt Reduction, Raised Outlook

Enhabit, Inc. reports robust third-quarter 2025 results with significant year-over-year growth in revenue and Adjusted EBITDA, alongside continued debt reduction and an updated positive full-year guidance.

Summary

• Consolidated net service revenue increased 3.9% year-over-year to $263.6 million in Q3 2025.
• Adjusted EBITDA grew 10.2% year-over-year to $27.0 million.
• Net income attributable to Enhabit, Inc. was $11.1 million, a significant improvement from a loss of $110.2 million in Q3 2024.
• Adjusted diluted EPS rose 466.7% to $0.17 from $0.03 in Q3 2024.
• Reduced total bank debt by $100.0 million since Q4 2023, resulting in $19.2 million in annualized cash interest savings.
• The leverage ratio improved to 3.9x, down from 4.9x in Q4 2023.
• Updated 2025 guidance for Adjusted EBITDA and Adjusted EPS upwards, while slightly narrowing the net service revenue range.

Sentiment

Score: 8

Explanation: The company reported strong financial performance with significant year-over-year growth in key metrics like Adjusted EBITDA and net income. Debt reduction efforts are consistent and effective, improving the balance sheet. The updated guidance is positive, raising expectations for full-year Adjusted EBITDA and EPS. Operational metrics show healthy growth in hospice and stabilization in home health, coupled with strong quality outcomes. The only minor negative is a slight sequential revenue dip in home health due to a temporary payer contract disruption, which has since been resolved.

Positives

• Consolidated net service revenue increased 3.9% year-over-year to $263.6 million.
• Adjusted EBITDA grew 10.2% year-over-year to $27.0 million.
• Net income attributable to Enhabit, Inc. significantly improved to $11.1 million from a $110.2 million loss in the prior year.
• Adjusted diluted EPS increased 466.7% year-over-year to $0.17.
• Home health year-over-year admissions grew 3.6%, with non-Medicare admissions increasing 10.4%.
• Home health average daily census (ADC) grew 3.7% year-over-year, with Medicare ADC decline stabilizing to (1.4)%.
• Hospice ADC grew 12.6% year-over-year, and admissions increased 1.4% (3.0% normalized for closures).
• Hospice net service revenue increased 20.0% year-over-year to $63.1 million.
• Hospice Adjusted EBITDA increased 72.0% year-over-year.
• Achieved the seventh straight quarter of debt prepayment, including an additional $10.0 million in Q4 2025.
• Reduced total bank debt by $100.0 million from Q4 2023, leading to $19.2 million in annualized cash interest savings.
• Leverage ratio improved to 3.9x from 4.9x in Q4 2023.
• Available liquidity increased to $143.3 million from $79.8 million at December 31, 2024.
• Updated 2025 guidance for Adjusted EBITDA ($106 to $109 million) and Adjusted EPS ($0.50 to $0.56) was raised.
• Strong quality outcomes: QoPC Star Rating of 3.1 (vs. national 3.0), HHCAHPS Star Rating of 4.0 (vs. national 3.7), 30-Day Hospital Readmission Rate of 14.1% (vs. national 18.0%), Patient Visits in Last Days of Life of 67.1% (vs. national 47.4%).

Negatives

• Home health net service revenue decreased 0.2% year-over-year to $200.5 million.
• Home health segment Adjusted EBITDA decreased 7.1% year-over-year to $33.9 million.
• Medicare home health admissions decreased 5.1% year-over-year.
• Home health revenue per patient day decreased 3.7% year-over-year to $52.6.
• Home health gross margin decreased to 46.3% from 47.3% year-over-year.
• Consolidated net service revenue was down (0.9)% sequentially due to temporary impact from national payer contract disruption.

Risks

• Ability to execute on strategic plans.
• Regulatory and other developments impacting the markets for services.
• Changes in reimbursement rates.
• General economic conditions.
• Changes in the episodic versus non-episodic mix of payers, patient case mix, and payment methodologies.
• Ability to attract and retain key management personnel and healthcare professionals.
• Potential disruptions or breaches of information systems (company, vendors, payers, contract counterparties).
• Outcome of litigation.
• Quality performance and ratings.
• Ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures.
• Ability to successfully integrate technology in operations.
• Ability to control costs, particularly labor and employee benefit costs.

Future Outlook

The company updated its 2025 guidance, raising the lower and upper ends for Adjusted EBITDA to $106 to $109 million and Adjusted EPS to $0.50 to $0.56. The net service revenue guidance was slightly narrowed to $1,058 to $1,063 million. This outlook anticipates continued growth in home health and hospice average daily census, with a focus on managing unit costs and optimizing revenue per patient day, alongside a continued shift towards non-Medicare admissions in home health.

Management Comments

• Our third quarter results reflect strong execution on our core strategic priorities, with year-over-year growth in revenue, census and Adjusted EBITDA.
• This progress allowed us to further reduce our bank debt and strengthen the balance sheet during the quarter.

Industry Context

The home health and hospice industry benefits from strong demographic tailwinds, including a rapidly aging population, with 75% of individuals aged 50 and over preferring to age in their homes. Home health care is significantly more cost-efficient, being 10 times lower in cost than other care settings like skilled nursing facilities. The market is substantial and growing, with projected Medicare skilled home health expenditures of approximately $41 billion and Medicare Hospice expenditures of approximately $32 billion by 2028. Enhabit's focus on expanding de novo locations and improving quality outcomes positions it to capitalize on these favorable trends, especially with its strong performance in hospice and stabilization of Medicare home health census declines.

Comparison to Industry Standards

• The company's Quality of Patient Care (QoPC) Star Rating of 3.1 is better than the national average of 3.0.
• The Home Health Care Consumer Assessment of Healthcare Providers (HHCAHPS) Patient Survey Star Rating of 4.0 is better than the national average of 3.7.
• The 30-Day Hospital Readmission Rate of 14.1% is significantly better than the national average of 18.0% (Research Institute for Home Care 2024 Chartbook).
• The percentage of patients receiving in-person visits from an RN or medical social worker on at least two of the final three days of life for hospice patients is 67.1%, which is substantially better than the Medicare fee-for-service claims data average of 47.4% (Medicare Provider Data catalog February 2025).
• The average Medicare cost per day for home health is $63, which is significantly lower than Skilled Nursing Facilities ($556) and Hospice ($186), aligning with the industry trend of cost-effective care in the home.

Legal Proceedings

• Nonroutine litigation is mentioned as an unusual or nonrecurring item impacting financial results, but no specific details on ongoing cases or their potential impact are provided.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased profitability, debt reduction, improved leverage ratio, and raised full-year guidance, which could lead to increased share value.
• Employees: Positive impact from a focus on engagement and retention, and improved clinical staff productivity. Restructuring activities and severance costs are mentioned as unusual items, which could indicate some workforce adjustments.
• Customers (Patients/Families): Positive impact from the company's focus on high-quality outcomes, as evidenced by better-than-average star ratings for quality of patient care and patient satisfaction, lower hospital readmission rates, and increased visits in the last days of life for hospice patients.
• Creditors: Positive impact from consistent debt reduction, improved leverage ratio, and strengthened balance sheet, indicating lower credit risk.
• Suppliers: No specific impact mentioned, but stable financial health generally benefits supplier relationships.

Next Steps

• Host an investor conference call on November 6, 2025, at 9:00 a.m. EST to discuss Q3 2025 results.
• Continue executing on strategic priorities including home health census growth, payer mix optimization, hospice ADC growth, opening de novo locations, optimizing existing de novo locations, de-levering the balance sheet, G&A expense management, improving cost per patient day, enhancing value-based performance, and focusing on patient/family experience, readmission rates, and employee engagement/retention.

Key Dates

Recommendation

The company demonstrates strong operational execution, particularly in its hospice segment and in stabilizing home health Medicare census. The significant year-over-year improvements in net income and Adjusted EBITDA, coupled with consistent and substantial debt reduction, point to a strengthening financial position. The upward revision of full-year Adjusted EBITDA and EPS guidance signals management's confidence in continued positive momentum. Furthermore, Enhabit's superior quality outcomes and alignment with favorable industry tailwinds (aging population, cost-effective home care) suggest a robust long-term growth trajectory. While home health revenue saw a slight sequential dip due to a temporary payer contract issue, its resolution and overall positive trends outweigh this minor setback, making the stock an attractive 'buy' for investors seeking exposure to the growing home healthcare sector.

Keywords

Home Health, Hospice, Healthcare Services, Adjusted EBITDA, Debt Reduction, Patient Care, Medicare, Non-Medicare, Admissions Growth, Average Daily Census, Financial Results, Q3 2025, EHAB, SEC Filing